Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Timolol + carboxymethylcellulose is a fixed-dose combination ophthalmic formulation containing timolol, a non-selective beta-adrenergic receptor antagonist (beta-blocker), and carboxymethylcellulose, an ocular lubricant and bioadhesive polymer. Timolol reduces intraocular pressure by decreasing aqueous humor production in the eye, making it effective for treating open-angle glaucoma and ocular hypertension. Carboxymethylcellulose acts as a lubricant to relieve dry or irritated eyes and enhances the retention time of timolol on the ocular surface, potentially improving tolerability and efficacy while reducing local toxicity associated with preservatives. This combination is designed to provide both intraocular pressure reduction and symptomatic relief of dry eye symptoms[1][2][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on timolol + carboxymethylcellulose.